Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment

1 Oct 2018

Abstract excerpt

BACKGROUND: Previous studies on the role of TP53 mutation in breast cancer treatment response and survival are contradictory and inconclusive, limited by the use of different endpoints to determine clinical significance and by small sample sizes that prohibit stratification by treatment. METHODS: We utilized large datasets to examine overall survival according to TP53 mutation status in patients across multiple...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer-related Molecular Pathways
Share to Telomeres, Telomerase, and Senescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30285883
DOI: 10.1186/s13058-018-1044-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatmentPMID 30285883Read ↗

p53 in breast cancer subtypes and new insights into response to chemotherapy.Semantic proximity Read ↗

p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.Semantic proximity Read ↗

Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trialSemantic proximity Read ↗

Alterations in the p53 isoform ratio govern breast cancer cell fate in response to DNA damageSemantic proximity Read ↗

TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective.Semantic proximity Read ↗

Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancerSemantic proximity Read ↗

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.Semantic proximity Read ↗

TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.Semantic proximity Read ↗

TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients.Semantic proximity Read ↗

p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors.Semantic proximity Read ↗

Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.Semantic proximity Read ↗

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.